Answers are grounded in this paper and cite their sources.
The global fight to stop tuberculosis (TB) remains a great challenge, particularly with the increase in drug‐resistant strains and a lack of funding to support the development of new treatments. To bolster a precarious drug pipeline, we prepared a focused panel of eight pentafluorosulfanyl (SF 5 ) compounds which were screened for their activity against Mycobacterium tuberculosis (Mtb) H37Rv in three different assay conditions and media. All eight compounds had sub‐micromolar potency, and four displayed MICs <100 n m . Seven compounds were evaluated against non‐replicating and mono‐drug‐resistant Mtb, and for their ability to inhibit Mtb within the macrophage. The greatest potency was observed against intracellular Mtb (MIC <10 n m for three compounds), which is often the most challenging to target. In general, the SF 5 ‐bearing compounds were very similar to their CF 3 counterparts, with the major differences observed being their in vitro ADME properties. Two SF 5 ‐bearing compounds were found to have greater protein binding than their corresponding CF 3 counterparts, but were also less metabolized in human microsomes, resulting in longer half‐lives.
No takes yet. Share an insight, caveat, or question.
Moraski et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: